BioDelivery Sciences International, Inc. (BDSI) is a specialized pharmaceutical firm dedicated to the advancement and commercialization of therapeutic products designed for long-term health conditions, serving markets both within the United States and internationally. The company's product offerings leverage its proprietary BioErodible MucoAdhesive drug delivery system—a slender, dissolving polymer film intended for application to the inner cheek—in addition to other drug administration methodologies. Its portfolio includes several key products: BELBUCA, a buprenorphine buccal film, is utilized for the ongoing management of persistent pain. Symproic functions as a peripherally acting mu-opioid receptor antagonist, specifically addressing opioid-induced constipation in adult patients suffering from chronic non-cancer pain. This also covers individuals whose chronic pain is a result of prior cancer or its treatment, provided they do not require frequent increases in opioid dosage. ELYXYB, an oral solution containing celecoxib, provides treatment for adult migraines, irrespective of the presence of an aura. ONSOLIS, a soluble fentanyl film administered buccally, is intended for the management of sudden, severe "breakthrough" pain experienced by cancer patients. Founded in 1997, BioDelivery Sciences International, Inc. is headquartered in Raleigh, North Carolina. As of March 18, 2022, the company operates as a subsidiary of Collegium Pharmaceutical, Inc.


Net sales
Gross margin
Net income